share_log

B of A Securities Downgrades FibroGen to Underperform, Lowers Price Target to $2

B of A Securities Downgrades FibroGen to Underperform, Lowers Price Target to $2

B of A 证券将FibroGen的评级下调至表现不佳,将目标股价下调至2美元
Benzinga ·  2023/08/08 08:49

B of A Securities analyst Jason Gerberry downgrades FibroGen (NASDAQ:FGEN) from Neutral to Underperform and lowers the price target from $4 to $2.

B of A Securities分析师杰森·格伯里将FibroGen(纳斯达克股票代码:FGEN)的评级从中性下调至表现不佳,并将目标股价从4美元下调至2美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发